

Synchrotron radiation in drug discovery

Helena Käck

Discovery Sciences
IMED Biotech Unit, AstraZeneca, Sweden

helena.kack@astrazeneca.com

Protein crystallography and structure-based drug design has long been integrated in project development within pharmaceutical companies. There are many examples describing how structural information has impacted the design of novel chemical compounds, which have progressed to clinical programs. Structural information on protein-ligand complexes has also opened up for alternative approaches to hit finding, such as fragment-based drug discovery.

Determination of high resolution protein structures to support drug discovery relies on frequent and regular access to synchrotron radiation. In this presentation I will discuss the use of structural information in drug discovery projects at AstraZeneca.